Neogen Reports Q3 FY2026 Financial Results: Key Details for Investors

Summary of Financial Performance

• Q3 FY2026 Revenue: \$211.2 million, down 4.4% year-over-year.
• Net Loss: \$17.0 million (GAAP EPS of \$(0.08)), compared to a \$10.9 million loss in the prior year (EPS \$(0.05)).
• Adjusted Net Income: \$19.4 million, or \$0.09 per diluted share (prior year: \$20.9 million, or \$0.10 per share).
• Adjusted EBITDA: \$48.2 million, margin of 22.8% (up from 22.0% prior year).
• Gross Margin: 46.9% (down from 49.9% last year) – impacted by Petrifilm manufacturing transition, tariffs, and inventory write-offs.
• Cash Flow from Operations: \$22.7 million, with free cash flow of \$11.1 million in the quarter.
• Nine-Month Revenues: \$645.1 million, down 3.6% year-over-year.

Business Segment Performance

Food Safety

• Q3 Revenue: \$156.7 million, up 2.6% year-over-year.
• Core Growth: 4.0% (excludes FX and M&A impacts).
• Notable growth in: Indicator Testing & Culture Media (up 11.0%), and international sales (+3.1%).

Animal Safety

• Q3 Revenue: \$54.5 million, down 20.1% year-over-year.
• Core Growth: (8.7)% – significant decline due primarily to third-party supplier challenges.
• Nine-month revenue: \$170.8 million, down 11.5% year-over-year.

Geographic Performance

• Domestic Revenue (Q3): \$102.3 million, down 11.4%.
• International Revenue (Q3): \$108.9 million, up 3.1%.

Operational and Strategic Highlights

• Petrifilm® Manufacturing Transition: Remains on track for completion by November FY2027. 100% of equipment validated, with operational and performance validation ongoing for multiple SKUs. Duplicative costs from this transition have weighed on margins but are expected to be temporary.
• Genomics Business Divestiture: Announced and expected to close in Q2 FY2027. Net cash proceeds will help target a net debt-to-adjusted EBITDA ratio of less than three times by the end of calendar year 2026. This is a significant portfolio reshaping move.
• Go-to-Market Strategy Review: Company is realigning resources to higher-return markets, standardizing global solutions-based selling, and implementing metric-based performance analysis under new commercial leadership.
• Cost Saving Initiatives: Higher adjusted EBITDA margin is attributed to cost-saving actions implemented at the end of Q1 FY2027, with efforts ongoing to further drive efficiency via technology and process improvements.
• Focus on Food Safety: Management is committed to building on its leadership position in Food Safety through disciplined operations, innovation, and improved sales processes.

Balance Sheet and Cash Flow

• Total Assets as of Feb 28, 2026: \$3.36 billion.
• Cash and Equivalents: \$53.3 million.
• Net Cash from Operating Activities (9 months): \$53.0 million.
• Net Cash from Investing Activities (9 months): \$74.5 million, including \$121.7 million from business sales.
• Reduction in Debt: \$100 million repaid in the period.
• Total Stockholders’ Equity: \$2.10 billion.

Guidance and Outlook

• Revenue Outlook Raised for FY2026: Management has increased its revenue outlook for the year, while maintaining adjusted EBITDA guidance – a sign of confidence despite operational headwinds.
• Operational Risks: The company continues to cite risks, especially related to supplier challenges (especially in Animal Safety), ongoing integration of 3M Food Safety, Petrifilm transition costs, and the successful execution of the genomics divestiture.

Risks and Forward-Looking Statements

• Neogen has identified a wide array of risks, including but not limited to: integration risks from acquisitions, supply chain and supplier dependency, manufacturing transition risks, IT and cybersecurity threats, regulatory changes, legal proceedings, competition, profitability pressures, and risks associated with substantial indebtedness.
• The company notes that various forward-looking statements are subject to known and unknown risks, and actual future results could differ materially from current expectations.

Potential Price-Sensitive Factors for Shareholders

• Genomics Divestiture: The announced sale is a significant portfolio move that could unlock value, reduce leverage, and sharpen the company’s focus on core food and animal safety operations.
• Petrifilm Transition: While currently weighing on gross margins due to duplicative costs, this manufacturing shift is pivotal for future efficiency and profitability. Successful completion could boost margins and investor confidence.
• Animal Safety Segment Weakness: Ongoing supplier challenges have resulted in a steep revenue decline in this segment. This is a material headwind but is described as “transient” by management, who are actively working on remediation.
• Improved Cost Controls: The sequential increase in adjusted EBITDA margin reflects successful cost-saving actions – a positive for ongoing profitability and free cash flow generation.
• Raised Revenue Outlook: Despite operational headwinds, management’s decision to raise the FY2026 revenue outlook signals optimism about the underlying business trajectory.

Conclusion

Neogen’s Q3 FY2026 results reflect resilience in Food Safety, operational challenges in Animal Safety, and a major strategic portfolio reshaping via the announced genomics divestiture. The Petrifilm manufacturing transition, while temporarily weighing on margins, is expected to be a future driver of efficiency. Investors should closely monitor the progress on these fronts, as well as management’s cost control and growth initiatives as the company navigates ongoing supply chain and integration headwinds.

Disclaimer: This article is for informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any shares. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions. All forward-looking statements are subject to risks and uncertainties as described in the company’s filings and may differ materially from actual results.

View NEOGEN CORP Historical chart here